InvestorsHub Logo
Followers 14
Posts 898
Boards Moderated 0
Alias Born 03/07/2011

Re: None

Tuesday, 06/24/2014 7:31:13 AM

Tuesday, June 24, 2014 7:31:13 AM

Post# of 2953
Baird Downgrades Enanta Pharmaceuticals (ENTA) to Neutral

http://www.streetinsider.com/Analyst+Comments/Baird+Downgrades+Enanta+Pharmaceuticals+%28ENTA%29+to+Neutral/9607317.html

Baird downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Outperform to Neutral with a price target of $41.00 on valuation.

Analyst Brian Skorney said, "At this price, we are firm believers that, fundamentally, ENTA is at fair value. However, we do note that the MRK/IDIX deal has injected some life into the HCV M&A game and Enanta offers one of the few remaining tickets into the space."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News